Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568397 · ClinicalTrials.gov registry record · Phase 1
A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02568397 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 60 participants.
The verdict
NCT02568397, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the effect of lanabecestat on how the body absorbs and processes dabigatran etexilate and how dabigatran etexilate affects lanabecestat when they are taken together. This study will last about 28 days and participants will be asked to take an lanabecestat tablet daily for 19 days and a dabigatran etexilate tablet on 3 occasions. Screening is required within 30 days prior to the start of the study.
Interventions
- DRUG Dabigatran etexilate
- DRUG Lanabecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-10-31 |
| Est. Completion | 2016-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568397
The ClinicalTrials.gov registry entry for NCT02568397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dabigatran etexilate is the first listed.
NCT02568397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02568397 about?
NCT02568397 is a clinical study titled "A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants". The purpose of this study is to learn about the effect of lanabecestat on how the body absorbs and processes dabigatran etexilate and how dabigatran etexilate affects lanabecestat when they are taken together. This study will last about 28 days and participants will be asked to take an lanabecestat ...
What is the current status of trial NCT02568397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-10-31. Estimated completion is 2016-01-31.
What interventions are being tested in trial NCT02568397?
The interventions under investigation include: Dabigatran etexilate (DRUG), Lanabecestat (DRUG).
Who is sponsoring clinical trial NCT02568397?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.